Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients

NCT00736229 · Completed

Last updated 2026-05-28

This trial tested whether giving exenatide through an IV to patients with high blood sugar in the cardiac ICU after a heart attack or related condition could help manage their glucose levels.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 40 people

Who can join Ages 18+ · all sexes

Timeline Started 2008-08 · est. completion 2012-08

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT00736229 ↗

Description as written by the study sponsor.

The purpose of this study is to determine the efficacy of intravenous Exenatide therapy in hyperglycemic patients admitted to the coronary intensive care unit.

Treatments tested

Exenatide also known as Byetta Drug

0.05 µg/min bolus of open-label exenatide followed by a constant infusion of 0.025 µg/min for 24-48 hours

Main thing measured	Median Glucose Values From Steady State Through 48 Hours or Until Discharge.
Sponsor	Saint Luke's Health System
Conditions studied	Hyperglycemia, Acute Coronary Syndromes, Myocardial Infarction
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00736229 ↗